• Receipts from customers totalled $14.6 million
• Strong operating performance with $1.5 million positive cash inflow
• Cash reserves reached a record $21.1 million, debt-free

EZZ Life Science Holdings Ltd (ASX: EZZ) presented its quarterly activity report and Appendix 4C cash flow statement for the period ended 31 March 2025 (Q3 FY25). The company reported receipts from customers totalling $14.6 million, reflecting lower seasonal turnover in January and February compared to the prior corresponding period, partly due to reduced digital advertising spend. Despite this, EZZ delivered strong operating performance, resulting in $1.5 million of positive cash inflow. The company's cash reserves reached a record $21.1 million as at 31 March 2025, with EZZ remaining debt-free, excluding lease liabilities. Key highlights during the quarter included the successful launch of two new products, strengthened domestic distribution with new retail pharmacy listings, progress on the company's strategic entry into the US market, elevated brand awareness through the inaugural sponsorship of the 2025 Australian Open, and continued momentum in the China market. EZZ also exhibited at key trade events, reinforcing its industry presence and global networking. Looking ahead, the company remains focused on executing its growth strategy through product innovation, market expansion, and strategic partnerships in key markets, with a strong pipeline of initiatives planned for Q4 FY25.

EZZ anticipates a strong finish to the financial year, historically its highest-performing quarter, with key priorities including a successful US market entry, capitalising on major shopping events in China, and pursuing strategic acquisition opportunities.

EZZ remains focused on executing its growth strategy through product innovation, market expansion and strategic partnerships in key markets. With a robust pipeline of initiatives planned for Q4 FY25, the company anticipates a strong finish to the financial year.